BioSpace News Archive

Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD). The preliminary data from 9 ambulatory boys with DMD, aged 6 to 12 (mean age: 8 years) indicate that the intravenous administration of PF-06939926 was well-tolerated during the infusion period, with encouraging efficacy and manageable safety events, eve

Significant Test Manufacturing Capacity, Large Installed Base of Automated Instruments Yield Testing Breakthrough --

LAIX Inc. (“LAIX” or the “Company”) (NYSE: LAIX), an artificial intelligence (AI) company in China that creates and delivers products and services to popularize English learning, today announced that Ms. Min (Jenny) Zhang has been appointed as an independent director to the Company’s board of directors (the “Board”), effective May 15, 2020

Silverback Therapeutics™ (“Silverback”), a biopharmaceutical company advancing a pipeline of therapies that are systemically delivered, but locally active, today announced that preclinical data supporting development of its lead ImmunoTAC™ candidate, SBT6050, has been a

ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, today announced that results from a proof of concept (PoC) study evaluating its proprietary immunotherapy platform, YourVaccx TM , for the treatment of patients with metastatic solid tumor cancers will be presented at the American Association for Cancer Research (AACR) 2020 Virtual Annua

HiFiBiO Therapeutics will take a pioneering approach to clinical development of its pipeline of antibody candidates by using patient stratification biomarkers identified by the company’s proprietary Drug Intelligent Science (DIS™) CAMBRIDGE, Mass. & SHANGHAI & PARIS--( BUSINESS WIRE )-- Scientists at HiFiBiO Therapeutics have generated preclinical data packages for novel monoclonal antibodies that demonstrate favorable clinical development

Cassava Sciences, Inc. (Nasdaq: SAVA) today reported top-line results from a Phase 2b study of PTI-125, its lead investigational drug, in patients with Alzheimer’s disease. This study did not meet its primary endpoint.

Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the presentation of new data at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II , taking place f

Beyond Air, Inc. announced that it has entered into a new common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC, a Chicago-based fundamentally focused, long-term institutional investor, for up to $40 million.

Beyond Air, Inc. announced an e-poster presentation at the upcoming American Association for Cancer Research Virtual Annual Meeting II being held from June 22nd to 24th.